Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression
Metrics: PDF 1115 views | HTML 2796 views | ?
Jiao Zou1,*, Linlin Zhu1,*, Xiaomei Jiang1, Yang Wang1, Yue Wang1, Xiangwei Wang2 and Bin Chen1
1Department of Biochemistry and Molecular Biology, Third Military Medical University, Chongqing 400038, China
2Department of Urology, Shenzhen University General Hospital, Shenzhen 518060, Guangdong, China
*These authors contributed equally to this work
Bin Chen, email: email@example.com
Keywords: FEN1; curcumin; cisplatin resistance; breast cancer; ERK
Received: February 04, 2017 Accepted: December 03, 2017 Published: January 10, 2018
Flap endonuclease 1 (FEN1) overexpression promotes breast cancer. We investigated the role of FEN1 in cisplatin resistance and the chemosensitizing effects of curcumin in breast cancer cells. We demonstrated that FEN1 overexpression promotes cisplatin resistance in breast cancer cells, and that FEN1 knockdown enhances cisplatin sensitivity. Curcumin down-regulated FEN1 expression in a dose-dependent manner. A combination of cisplatin and curcumin enhanced breast cancer cell sensitivity to cisplatin by down-regulating FEN1 expression in vitro and in vivo. Increased ERK phosphorylation contributed to cisplatin resistance and cisplatin-induced FEN1 overexpression in breast cancer cells. Inhibiting ERK phosphorylation stimulated the chemosensitizing effect of curcumin to cisplatin by targeting FEN1. These data reveal that FEN1 overexpression promotes cisplatin resistance, and suggest FEN1 could be a potential therapeutic target to relieve cisplatin resistance in breast cancer. We also demonstrated that curcumin sensitizes breast cancer cells to cisplatin through FEN1 down-regulation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.